Ryan O’Keefe: Diagnostic Insights Into High-Risk Myelodysplastic Syndrome
Ryan O’Keefe, Internal Medicine Resident at the Hospital of The University of Pennsylvania, Creator of Point of Care Medicine, shared a post on X:
“Daily Pearl(s):
High-Risk Myelodysplastic Syndrome (MDS) with U2AF1 Mutation.
The triad of unexplained systemic inflammation (high ESR/CRP), progressive cytopenias, and an opportunistic infection (such as candida esophagitis) should raise suspicion for an underlying hematologic malignancy like MDS.
In complex cases with multiple problems, systematically evaluate each one before attempting to unify them – pursuing a red herring as part of a systemic process can be dangerously misleading.
Bilateral adrenal hemorrhage is a medical emergency and can be a rare paraneoplastic manifestation of MDS, which creates a paradoxical state of thrombosis (from inflammation) and hemorrhage (from thrombocytopenia).
Clonal hematopoiesis (MDS, VEXAS syndrome) is an increasingly recognized cause of severe seronegative or atypical autoimmune and vasculitic syndromes, particularly in older adults.
When persistent, unexplained cytopenias and systemic illness remain after extensive infectious and rheumatologic workups, bone marrow biopsy with genetic testing can be a critical diagnostic step.
MDS impairs innate immune function, predisposing patients to opportunistic fungal infections even without classic risk factors like chemotherapy or high-dose steroids.
High-risk MDS is treated with hypomethylating agents (azacitidine) or, in eligible patients, allogeneic stem cell transplantation.
Spliceosome mutations (U2AF1, SF3B1, SRSF2) and UBA1 mutations (VEXAS) are key driver variants to know.
Source: April 11, 2026 Simplicity in Complexity VMR with Jeffrey and Kirtan – dyspnea and vision loss.”
Stay updated with Hemostasis Today.
-
Jun 30, 2026, 14:40A Patient-Centered Approach on Hormone Therapy Following Thrombosis – Thrombosis Canada
-
Jun 30, 2026, 14:32Lindsey George: Blood Study Links AAV-Derived FVIII Activity to Clinical Outcomes
-
Jun 30, 2026, 10:01Robert Lufkin: Stop Eating 3 Hours Before Bed
-
Jun 30, 2026, 09:52Kathleen Freson: Opportunities to Lead Thrombosis and Hemostasis in ISTH
-
Jun 30, 2026, 09:40Farid Abedrabbo: How High b-Values Improve Ischemia Detection
-
Jun 30, 2026, 09:29Imran Khan: Balancing Benefit and Risk in Long-Term Anticoagulation
-
Jun 30, 2026, 08:23Have You Registered for the EHC Annual Conference 2026 Yet?
-
Jun 30, 2026, 08:03Joaqim Meireles-Brandao: From Isolated LDL-C to The Global Assessment of Total Atherogenic Burden
-
Jun 30, 2026, 06:43Haileraguel Hailemichael: Antiphospholipid Syndrome Testing – When Blood Clots Point to an Autoimmune Cause